文献速递乳腺癌

Zanidatamab联合哌柏西利和氟维司群治疗经治激素受体阳性HER2阳性转移性乳腺癌:两部分、多中心、单臂2a期研究主要结果

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.
PubMed 文献 · Lancet Oncol · 2025-05-05

这项在西班牙、加拿大和美国13家中心开展的单臂2a期研究,评估zanidatamab联合哌柏西利和氟维司群治疗经治激素受体阳性HER2阳性转移性乳腺癌。51例患者中位既往HER2靶向治疗4线,6个月无进展生存率66.7%,常见不良事件为腹泻和中性粒细胞减少,未见治疗相关死亡。

要点

  • 51例经治HER2阳性转移性乳腺癌患者接受zanidatamab联合哌柏西利和氟维司群治疗。
  • 6个月无进展生存率为66.7%(95%CI 52.1-79.2)。
  • 3-4级治疗相关不良事件发生34例(67%),最常见为中性粒细胞减少26例(51%)。

核心结论

  • Zanidatamab联合哌柏西利和氟维司群总体安全并显示出有前景的抗肿瘤活性,支持进一步评估该无化疗三药方案。

研究设计与样本

  • 多中心、单臂、两部分2a期研究,在西班牙、加拿大和美国的13所大学医院、癌症中心或研究所开展。
  • 纳入年龄≥18岁、ECOG体能状态0或1、病理确诊不可切除或转移性乳腺癌、局部评估激素受体阳性和HER2阳性、既往HER2靶向治疗期间或之后疾病进展的患者。
  • 51例患者入组:第1部分8例(2020年6月10日至2021年2月7日),第2部分43例(2021年2月8日至2022年10月31日)。
  • 第1部分主要终点为三药联合的安全性和确认第2部分推荐剂量;第2部分主要终点为6个月无进展生存率。

主要发现

  • 51例患者中49例(96%)女性、2例(4%)男性,中位年龄54.0岁(46.0-62.0),42例(82%)白人。
  • 中位随访16.1个月(IQR 9.9-23.4),三药方案中位治疗持续时间7.4个月(3.4-14.8),中位既往HER2靶向治疗4线(IQR 3-4),12例(24%)曾接受德曲妥珠单抗。
  • 全部51例患者发生至少1项任何级别治疗相关不良事件,最常见为腹泻41例(80%),其中34例(67%)为1-2级。
  • 3或4级治疗相关不良事件发生在34例(67%)患者,最常见为中性粒细胞减少26例(51%);1例(2%)发生3级转氨酶升高的严重治疗相关不良事件;无治疗相关死亡。
  • 总体样本(N=51)中,6个月无进展生存率为66.7%(95%CI 52.1-79.2)。

关键数值与推荐

  • 第1部分起始剂量:zanidatamab 20 mg/kg静脉注射,每2周一次,于28天周期的第1天和第15天给药。
  • 哌柏西利125 mg口服,每日一次,每周期第1-21天给药。
  • 氟维司群500 mg肌内注射,前三次每2周一次(第1周期:第1天和第15天;第2周期:第1天),之后每4周一次(后续所有周期:第1天)。
  • 第1部分计划的起始药物剂量被确认为第2部分推荐剂量,全部51例患者均按推荐剂量治疗。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New HER2-targeted regimens, including chemotherapy-free options, are needed for metastatic breast cancer. In an ongoing, two-part, phase 2a study, we assessed the safety and antitumour activity of zanidatamab, a HER2-targeted bispecific antibody, plus palbociclib and fulvestrant, in heavily pretreated patients with hormone receptor-positive, HER2-positive advanced or metastatic breast cancer. METHODS: This multicentre, single-arm, two-part, phase 2a study is being conducted at 13 university hospitals, cancer centres, or research institutes in Spain, Canada, and the USA. Eligible patients were adults (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1, and with pathologically confirmed unresectable or metastatic breast cancer, assessed locally to be hormone receptor-positive and HER2-positive, with disease progression during or after previous HER2-targeted therapies. Patients were enrolled in part 1, part 2, or part 1 followed by part 2. In part 1, patients received starting doses of zanidatamab (20 mg/kg intravenously once every 2 weeks on days 1 and 15 of a 28-day cycle) with palbociclib (125 mg orally once a day on days 1-21 of each cycle) and fulvestrant (500 mg intramuscular injection once every 2 weeks for the first three doses [cycle 1: days 1 and 15, cycle 2: day 1], then once every 4 weeks [all subsequent cycles: day 1]). In part 1, primary endpoints were safety of the triplet combination and confirmation of recommended doses for part 2. In part 2, patients received the recommended doses confirmed in part 1, and the primary endpoint was progression-free survival at 6 months. Safety and progression-free survival were assessed in all enrolled patients who received any dose of zanidatamab, palbociclib, or fulvestrant. Patients in part 1 who were treated at the recommended doses were analysed together with the patients in part 2. This study is registered with ClinicalTrials.gov, NCT04224272, and is active with recruitment completed. FINDINGS: Overall, 51 patients (49 [96%] female and two [4%] male; median age 54·0 [46·0-62·0] years; 42 [82%] White) were enrolled: eight in part 1 (June 10, 2020-Feb 7, 2021) and 43 in part 2 (Feb 8, 2021-Oct 31, 2022). All 51 patients had received study treatment at the data cutoff (Aug 3, 2023); median follow-up was 16·1 months (IQR 9·9-23·4) and the median duration of triplet regimen treatment was 7·4 months (3·4-14·8). The median number of previous HER2-targeted therapies was 4 (IQR 3-4). 12 (24%) of 51 patients had previously received trastuzumab deruxtecan. The planned starting drug doses administered in part 1 of the study were confirmed as the recommended doses for part 2. All 51 patients were treated at the recommended doses. All 51 patients had at least one treatment-related adverse event of any grade, with diarrhoea being the most common (41 [80%] patients, with 34 [67%] having grade 1-2 events). Grade 3 or 4 treatment-related adverse events occurred in 34 (67%) patients, with neutropenia being the most common (26 [51%] patients). One (2%) patient had a serious grade 3 treatment-related adverse event of increased transaminases. No treatment-related deaths occurred. In the overall sample (N=51), progression-free survival at 6 months was 66·7% (95% CI 52·1-79·2). INTERPRETATION: Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising antitumour activity, supporting further evaluation of this chemotherapy-free triplet regimen. FUNDING: Zymeworks, Jazz Pharmaceuticals, and Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Escrivá-de-Romani S, Cejalvo JM, Alba E, et al. Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. Lancet Oncol. 2025. PMID: 40339592. doi:10.1016/S1470-2045(25)00140-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。